Results 51 to 60 of about 2,582 (154)

Metastatic survival curves stratified by treatment modalities in different number of metastases: oligometastasis (A) and multimetastasis (B).

, 2016
Metastatic survival curves stratified by treatment modalities in different number of metastases: oligometastasis (A) and multimetastasis (B).
Chuanben Chen (845333), Juhui Chen (845331), Junxin Wu (845332), Jianji Pan (588865), Jingfeng Zong (588861), Chaobin Huang (561304), Shaojun Lin (588862), Wei Zheng (25452)   +7 more
core   +1 more source

Modern approach in oligometastatic prostate cancer therapy [PDF]

Medicinski Podmladak, 2023
Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Oligometastatic prostate cancer is generally defined by the presence of five or fewer metastatic sites on imaging.
Stanić Jelena, Nikitović Marina, Miletić Nebojša, Stanković Vesna   +3 more
doaj  

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Oligometastatic Head and Neck Cancer: Challenges and Perspectives

, 2022
SIMPLE SUMMARY: Oligometastasis represents a disease state and an opportunity for cure when metastases emerge. Emerging evidence supports that most head and neck cancer patients with oligometastatic disease are likely to benefit from curative intent ...
Shao Hui Huang, O’Sullivan, Brian, Huang, Shao Hui, Brian O’Sullivan, Bahig, Houda, Houda Bahig   +5 more
core   +1 more source

Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms

Cancer Medicine, Volume 15, Issue 5, May 2026.
NCCT radiomics for surufatinib efficacy prediction in HM‐NENs. ABSTRACT Background Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs.
Miaomiao Feng, Man Zhao, Xiaoling Duan, Jiaojiao Hou, Qi Wang, Fei Yin   +5 more
wiley   +1 more source

Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy

Respirology Case Reports, 2020
A 63‐year‐old man suspected of having lung cancer underwent right upper lobectomy and was diagnosed with large cell neuroendocrine carcinoma (LCNEC). Eleven months after surgery, he developed an oligorecurrence in the adrenal gland and underwent left ...
Hiroki Sato, Motoko Tachihara, Tatsunori Kiriu, Masatsugu Yamamoto, Yugo Tanaka, Yoshihiro Nishimura   +5 more
doaj   +1 more source

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Hepatology Research, Volume 56, Issue 5, Page 830-839, May 2026.
ABSTRACT Background Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline
Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Emi Tanaka, Toshifumi Tada, Tetsuya Yasunaka, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Masahiro Sakata, Motoyuki Otsuka   +20 more
wiley   +1 more source

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease

Current Oncology, 2022
Stereotactic body radiotherapy (SBRT) and percutaneous thermal ablation (TA) are alternatives to surgery for the management of pulmonary oligometastases.
Alban Macagno, Alexandre de Nonneville, Pierre Annede, Gilles Piana, Isabelle Pougnet, Nassima Daidj, Laurence Moureau-Zabotto, Julien Darreon, Laetitia Padovani, Francois Bertucci, Naji Salem   +10 more
doaj   +1 more source

Quantifying setup uncertainty between computed tomography guidance and magnetic resonance guidance in intramuscular metastases radiotherapy

Journal of Applied Clinical Medical Physics, Volume 27, Issue 4, April 2026.
Abstract Background and purpose MR‐Linac (MRL) is well‐suited for treatment of oligometastatic disease (OMD) in muscle due to its superior soft tissue contrast. The purpose of this study was to assess dosimetric differences and quantify margins when CT‐guidance (CTgRT) is used for OMD treatment compared to MR‐guidance (MRgRT) on the MRL.
Travis Salzillo, Surendra Prajapati, Zhiqian Henry Yu, Yao Zhao, Tze Yee Lim, He Wang, Xin A. Wang, Xinru Chen, Rajat Kudchadker, Belinda Lee, Angela Sobremonte, Ahsan S. Farooqi, Devarati Mitra, Andrew Bishop, Chad Tang, Jinzhong Yang   +15 more
wiley   +1 more source

Research Progress and Challenges of Oligometastasis in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer
Oligometastasis represents a transitional state between early localized disease and widespread metastasis, characterized by limited tumor burden and distinct tumor biological behavior.
Songzhen LI, Tianhang SHAO, Shuyang YAO
doaj   +1 more source